Share
Fred Guerard
Qlaris Bio, Inc., a clinical-stage biotech developing therapies for glaucoma, has appointed Fred Guerard, Pharm.D., as President and Chief Executive Officer.
He will also join the company’s Board of Directors.
Dr. Guerard brings more than 20 years of global leadership experience in ophthalmology and biotechnology, with a strong track record of advancing innovative therapies through late-stage development and toward commercialization. His appointment comes as the company continues to progress its clinical pipeline and strengthen its strategic direction.
He succeeds Thurein Htoo, who played a key role in establishing Qlaris Bio and advancing its development programs. Htoo will remain with the company until April 1, 2026, to support a smooth leadership transition.
Most recently, Dr. Guerard served as CEO of Opthea, where he enhanced the company’s strategic and financial position while advancing its pivotal programs. Prior to that, he was President and CEO of Graybug Vision, leading the company through Series C financing and its initial public offering. He also spent two decades at Novartis, including serving as Worldwide Franchise Head of Ophthalmology, where he managed global portfolios and executed key strategic transactions.
Dr. Guerard holds degrees from the University of Rouen and HEC Paris and currently serves on multiple biotech boards.
